175 related articles for article (PubMed ID: 12913319)
1. Tumour regression of uveal melanoma after ruthenium-106 brachytherapy or stereotactic radiotherapy with gamma knife or linear accelerator.
Georgopoulos M; Zehetmayer M; Ruhswurm I; Toma-Bstaendig S; Ségur-Eltz N; Sacu S; Menapace R
Ophthalmologica; 2003; 217(5):315-9. PubMed ID: 12913319
[TBL] [Abstract][Full Text] [Related]
2. Early ultrasonographic tumor regression after linear accelerator stereotactic fractionated photon radiotherapy of choroidal melanoma as a predictor for metastatic spread.
Mitsch C; Zehetmayer M; Gleiss A; Georg D; Dieckmann K; Pötter R; Sayegh R; Schmidt-Erfurth U; Dunavoelgyi R
Radiother Oncol; 2018 Jun; 127(3):385-391. PubMed ID: 29747872
[TBL] [Abstract][Full Text] [Related]
3. One-day session LINAC-based stereotactic radiosurgery of posterior uveal melanoma.
Furdova A; Strmen P; Waczulikova I; Chorvath M; Sramka M; Slezak P
Eur J Ophthalmol; 2012; 22(2):226-35. PubMed ID: 21534252
[TBL] [Abstract][Full Text] [Related]
4. Changes in ultrasound findings in posterior uveal melanoma after Ruthenium 106 brachytherapy.
Kaiserman I; Anteby I; Chowers I; Blumenthal EZ; Kliers I; Pe'er J
Ophthalmology; 2002 Jun; 109(6):1137-41. PubMed ID: 12045056
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium-106 plaque brachytherapy for uveal melanoma.
Tarmann L; Wackernagel W; Avian A; Mayer C; Schneider M; Winkler P; Langmann G
Br J Ophthalmol; 2015 Dec; 99(12):1644-9. PubMed ID: 25979763
[TBL] [Abstract][Full Text] [Related]
6. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: evaluation of 175 patients treated with 150 Gy from 1981-1989.
Pötter R; Janssen K; Prott FJ; Widder J; Haverkamp U; Busse H; Müller RP
Front Radiat Ther Oncol; 1997; 30():143-9. PubMed ID: 9205894
[No Abstract] [Full Text] [Related]
7. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
Böker A; Pilger D; Cordini D; Seibel I; Riechardt AI; Joussen AM; Bechrakis NE
Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
[TBL] [Abstract][Full Text] [Related]
8. Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma.
Takiar V; Gombos DS; Mourtada F; Rechner LA; Lawyer AA; Morrison WH; Garden AS; Beadle BM
Pract Radiat Oncol; 2014; 4(4):e189-94. PubMed ID: 25012839
[TBL] [Abstract][Full Text] [Related]
9. Complications in patients with uveal melanoma after stereotactic radiosurgery and brachytherapy.
Furdova A; Strmen P; Sramka M
Bratisl Lek Listy; 2005; 106(12):401-6. PubMed ID: 16642665
[TBL] [Abstract][Full Text] [Related]
10. Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma.
Kaiserman I; Anteby I; Chowers I; Blumenthal EZ; Kliers I; Pe'er J
Br J Ophthalmol; 2004 Jul; 88(7):892-5. PubMed ID: 15205232
[TBL] [Abstract][Full Text] [Related]
11. Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas.
Espensen CA; Appelt AL; Fog LS; Thariat J; Gothelf AB; Aznar MC; Kiilgaard JF
Acta Oncol; 2020 Aug; 59(8):918-925. PubMed ID: 32412331
[No Abstract] [Full Text] [Related]
12. Stereotactic radiosurgery and fractionated stereotactic radiotherapy in the treatment of uveal melanoma.
Henderson MA; Shirazi H; Lo SS; Mendonca MS; Fakiris AJ; Witt TC; Worth RM; Timmerman RD
Technol Cancer Res Treat; 2006 Aug; 5(4):411-9. PubMed ID: 16866571
[TBL] [Abstract][Full Text] [Related]
13. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation.
Krohn J; Monge OR; Skorpen TN; Mørk SJ; Dahl O
Eye (Lond); 2008 Nov; 22(11):1398-403. PubMed ID: 17585309
[TBL] [Abstract][Full Text] [Related]
14. Ruthenium-106 brachytherapy.
Pe'er J
Dev Ophthalmol; 2012; 49():27-40. PubMed ID: 22042011
[TBL] [Abstract][Full Text] [Related]
15. Ultrasonic mirror image from ruthenium plaque facilitates calculation of uveal melanoma treatment dose.
Espensen CA; Jensen PK; Fog LS; Appelt AL; Klemp K; Fledelius HC; Specht L; Kiilgaard JF
Br J Ophthalmol; 2017 Sep; 101(9):1206-1210. PubMed ID: 28159770
[TBL] [Abstract][Full Text] [Related]
16. Tumour cell proliferation after failed ruthenium plaque radiotherapy for posterior uveal melanoma.
Seregard S; Lundell G; Lax I; af Trampe E; Kock E
Acta Ophthalmol Scand; 1997 Apr; 75(2):148-54. PubMed ID: 9197561
[TBL] [Abstract][Full Text] [Related]
17. High dose rate and low dose rate ruthenium brachytherapy for uveal melanoma. No association with ocular outcome.
Fili M; Lundell G; Lundell M; Seregard S
Br J Ophthalmol; 2014 Oct; 98(10):1349-54. PubMed ID: 24825846
[TBL] [Abstract][Full Text] [Related]
18. Results of ruthenium irradiation of uveal melanoma.
Tjho-Heslinga RE; Kakebeeke-Kemme HM; Davelaar J; de Vroome H; Bleeker JC; Oosterhuis JA; Leer JW
Radiother Oncol; 1993 Oct; 29(1):33-8. PubMed ID: 8295985
[TBL] [Abstract][Full Text] [Related]
19. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.
Kaiserman N; Kaiserman I; Hendler K; Frenkel S; Pe'er J
Br J Ophthalmol; 2009 Sep; 93(9):1167-71. PubMed ID: 19570767
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma.
Furdova A; Sramka M; Chorvath M; Kralik G; Furda R; Gregus M
Melanoma Res; 2017 Oct; 27(5):463-468. PubMed ID: 28520637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
